By Business of Health Care Desk
June 18, 2026
The bedrock of the Medicare Advantage (MA) program—the quality-based "star rating" system—is currently undergoing a period of unprecedented volatility. Federal officials at the Centers for Medicare and Medicaid Services (CMS) have confirmed that they are once again recalculating the quality ratings for 2026 Medicare Advantage plans. This latest administrative pivot, disclosed in a recent government memo, is the direct result of a sustained, multi-front legal offensive waged by the nation’s largest health insurance carriers.
For years, the star rating system was viewed as a stable, if complex, metric used to reward high-performing plans. Today, it has become the primary theater of a high-stakes financial war. With $16 billion in annual taxpayer-funded bonuses hanging in the balance, insurers are increasingly turning to federal courts to challenge the methodology behind these scores, arguing that CMS calculations are not only flawed but fiscally damaging to their bottom lines.
The Core Conflict: Quality Bonuses vs. Administrative Discretion
At the heart of the dispute is the Quality Bonus Payment (QBP) program. Medicare Advantage plans that achieve a rating of four stars or higher out of five receive significant financial incentives from the federal government. These bonuses are intended to reward plans that provide superior care, manage chronic conditions effectively, and ensure high member satisfaction.
However, the size of this incentive pool has ballooned. In 2026, these bonuses reached $16 billion—a figure that now rivals the entire annual budget of the Centers for Disease Control and Prevention (CDC). Since 2020, the amount of money flowing through this bonus system has doubled, making even minor fluctuations in a plan’s star rating a matter of immense financial consequence. A shift of even a fraction of a point can mean the difference between hundreds of millions of dollars in revenue or a sharp decline in profitability.
Insurers argue that CMS’s methodology for calculating these ratings—which relies on a blend of clinical performance measures and patient satisfaction surveys—is opaque and prone to administrative error. CMS, conversely, maintains that its rigorous standards are necessary to ensure that taxpayer dollars are only allocated to plans that truly deliver value to the Medicare population.
Chronology of a Regulatory Breakdown
The current state of legal gridlock did not emerge overnight. It is the culmination of years of escalating tension between private industry and the federal regulator.
- 2020–2022: The Growth Phase: As Medicare Advantage enrollment surged, so did the reliance on star ratings. Insurers invested heavily in "star optimization" programs, viewing the bonus payments as a critical component of their growth strategy.
- 2023: The Wave of Litigation Begins: Frustrated by perceived inconsistencies in how CMS evaluated patient experience and administrative performance, major insurers began filing lawsuits. These suits challenged everything from the weighting of specific metrics to the way call center data was audited.
- 2024: The First Major Redo: A turning point occurred two years ago when federal judges ruled that CMS had erred in its original calculations for the 2024 plan year. The ruling forced the agency to recalculate ratings for the entire industry, creating massive uncertainty for beneficiaries and brokers alike.
- 2025: The Year of "Inundation": Legal action intensified, with industry giants like Elevance, Humana, and UnitedHealth Group filing separate challenges. These cases targeted diverse aspects of the scoring process, from technical data errors to broader disagreements over how "quality" is defined in a post-pandemic healthcare landscape.
- 2026: The New Recalculation: Following the latest round of judicial scrutiny, CMS has been forced to pause and pivot once more, triggering the current recalculation of 2026 ratings.
Supporting Data: The Economic Gravity of Star Ratings
To understand why insurers are willing to spend millions on litigation, one must look at the data. According to data from the Kaiser Family Foundation (KFF) and reports provided to Congress by MedPAC, the reliance on quality bonuses has become a systemic risk.
The Financial Stakes
- Bonus Inflation: The $16 billion in 2026 bonuses represents a 100% increase over 2020 levels.
- Market Impact: For major publicly traded insurers, a drop of even 0.5 stars in a regional rating can lead to a significant drop in stock price and a reduced ability to bid competitively for new members in the following enrollment season.
- The "All-or-Nothing" Threshold: Because the bonus structure is binary—you either hit the four-star threshold or you don’t—the "cliff effect" is severe. Insurers are incentivized to litigate because the loss of bonus eligibility is often an existential threat to the profitability of their regional MA products.
Official Responses and Regulatory Posture
The stance from CMS has been one of defensive compliance. In official memos, the agency has reiterated its commitment to the integrity of the Star Rating program. CMS officials argue that the legal challenges are an attempt by the industry to prioritize shareholder returns over the clinical outcomes the program was designed to incentivize.
"The integrity of the Medicare Advantage program relies on accurate and transparent measurement," a CMS spokesperson noted in recent briefings. "While we acknowledge the complexities of our methodology, we maintain that our calculations are grounded in the statutory requirements to ensure beneficiaries have access to high-quality coverage."
Meanwhile, industry trade groups, such as AHIP (America’s Health Insurance Plans), have maintained a more nuanced position. While not commenting on specific lawsuits, these groups have consistently called for more transparency from CMS regarding the "black box" of rating algorithms. They argue that if the government is going to tie billions of dollars to a metric, that metric must be mathematically verifiable and free from arbitrary administrative shifts.
Implications: A System in Transition
The ongoing legal battles carry profound implications for the future of the Medicare program.
1. Market Instability for Beneficiaries
The most immediate impact of the constant recalculations is the uncertainty it creates for seniors. When plans see their ratings fluctuate, they may be forced to change their benefit packages, increase premiums, or alter their provider networks mid-cycle to compensate for the loss of bonus revenue. This creates a "churn" effect that can disrupt care for the most vulnerable populations.
2. The Erosion of Public Trust
As the star rating system becomes increasingly associated with litigation rather than clinical excellence, the value of the "star" itself is diminished. If consumers and policy experts begin to view the ratings as a product of legal maneuvering rather than healthcare quality, the entire premise of the Medicare Advantage quality-based model may be undermined.
3. The Future of CMS Methodology
The trend of judicial intervention suggests that the courts may continue to act as a secondary regulator. If judges continue to rule against CMS’s calculation methods, the agency will likely be forced to move toward a more rigid, perhaps less nuanced, scoring system to avoid future litigation. This could lead to a "lowest common denominator" approach to quality measurement, which would arguably benefit no one.
4. Congressional Oversight
With $16 billion of taxpayer money on the line, pressure is mounting for Congress to intervene. Legislative proposals to reform the star rating system—perhaps by shifting the responsibility to an independent body or codifying the methodology into law to prevent CMS from making unilateral, and therefore contestable, changes—are likely to gain traction in the coming sessions.
Conclusion
The battle over Medicare Advantage star ratings is far more than a technical dispute between insurers and the government. It is a fundamental struggle over the future of the Medicare program. As the line between clinical care and financial optimization continues to blur, the "star" system—once a simple guide for seniors—has become a high-stakes battlefield. Until a more stable, transparent, and legally defensible framework is established, the $16 billion question will continue to dominate the business of American healthcare, leaving patients, providers, and insurers caught in the crossfire of an increasingly litigious regulatory environment.
